Tyronib400 mg

Tyronib is an oral tyrosine kinase inhibitor used, under the supervision of an oncologist/hematologist, in the following disease states classified by strength of evidence:

FDA-Approved / Established Indications

• Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, in adult and pediatric patients.
• Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, in adults and children.
• Relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults, generally used as a single agent.
• Newly diagnosed Ph+ ALL in adult and pediatric patients, in combination with chemotherapy.
• Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements, in adults.
• Aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation, or with unknown c-Kit mutation status, in adults.
• Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα fusion kinase (or FIP1L1-PDGFRα-negative/unknown), in adults.
• Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP), in adults.
• Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST), in adults.
• Adjuvant treatment after surgical resection of Kit-positive GIST, in adults.

Because of the seriousness of these conditions and the need for individualized dosing and close monitoring, Tyronib should only be initiated and supervised by a physician experienced in the management of hematologic malignancies or sarcomas.

Each film-coated tablet/capsule contains Imatinib Mesylate equivalent to 100 mg or 400 mg of imatinib base, along with pharmaceutically acceptable excipients such as microcrystalline cellulose, crospovidone, hydroxypropyl methylcellulose, magnesium stearate, colloidal silicon dioxide, and film-coating agents.

Tyronib is a small-molecule, orally administered tyrosine kinase inhibitor (TKI) that selectively blocks the abnormal BCR-ABL tyrosine kinase enzyme produced in Philadelphia chromosome-positive leukemias, as well as several other tyrosine kinases including c-Kit and platelet-derived growth factor receptor (PDGFR). It represented a major advance in targeted cancer therapy and is considered first-line treatment for many patients with Ph+ CML and Kit-positive GIST. It is dispensed only against a specialist's prescription and requires regular clinical and laboratory monitoring throughout treatment.

Antineoplastic agent - BCR-ABL tyrosine kinase inhibitor (targeted small-molecule cancer therapy). Tyronib belongs to the class of signal transduction inhibitors used in the treatment of specific leukemias and solid tumors.

Imatinib Mesylate inhibits the constitutively active BCR-ABL tyrosine kinase, which is produced by the Philadelphia chromosome translocation and drives uncontrolled proliferation of leukemic cells in CML and Ph+ ALL. It also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGFR) and stem cell factor (c-Kit/CD117), as well as PDGFR-related fusion kinases (e.g., FIP1L1-PDGFRα), which accounts for its activity in GIST, certain myelodysplastic/myeloproliferative diseases, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans. By blocking these kinases, Imatinib Mesylate inhibits proliferation and induces apoptosis in cells that depend on these abnormal signaling pathways, while sparing most normal cells.

Pharmacokinetics

Imatinib Mesylate is well absorbed orally (absolute bioavailability approximately 98%), extensively bound to plasma proteins (mainly albumin and alpha-1 acid glycoprotein), and metabolized primarily by the hepatic CYP3A4 enzyme (with minor contributions from CYP1A2, CYP2D6, CYP2C9, and CYP2C19) to an active metabolite. Elimination is mainly via feces, with a mean terminal half-life of approximately 18 hours for imatinib and 40 hours for its active metabolite, supporting once-daily dosing.

Take Tyronib orally with a meal and a large glass of water to minimize gastrointestinal irritation. Doses of 400 mg and above that require twice-daily dosing should be split into two equal doses (morning and evening). Tablets/capsules should be swallowed whole; if a patient cannot swallow, they may be dispersed in a glass of water or apple juice (approximately 50 mL for a 100 mg dose, 200 mL for a 400 mg dose) and taken immediately. Do not crush unless directed by the prescriber.

Tyronib is metabolized mainly by CYP3A4 and is itself an inhibitor of CYP3A4 and CYP2D6, resulting in clinically important interactions:

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, dexamethasone, St. John's Wort) can markedly reduce imatinib plasma levels and efficacy; concurrent use should generally be avoided, and if unavoidable, the dose of Tyronib may need to be increased by at least 50% under close monitoring.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice) can increase imatinib levels and toxicity risk; concurrent use should be avoided or undertaken with caution and monitoring.
• Warfarin: Patients on Tyronib who require anticoagulation should be switched to low-molecular-weight or standard heparin rather than warfarin, since imatinib can alter warfarin metabolism and increase bleeding risk.
• Acetaminophen (paracetamol): Use with caution, particularly at high or prolonged doses, due to a potential increase in hepatotoxicity risk when combined with Tyronib; avoid regular high-dose use.
• CYP3A4 substrates (e.g., certain statins such as simvastatin, cyclosporine, pimozide, some benzodiazepines): Tyronib may increase their plasma concentrations, raising the risk of toxicity; dose adjustment or closer monitoring may be needed.
• Levothyroxine: Patients who have undergone thyroidectomy and are on levothyroxine replacement may need dose adjustment, as Tyronib can lower levothyroxine plasma levels.

Always inform the prescribing physician about all other medicines, supplements, and herbal products being used before and during treatment with Tyronib.

Adverse effects of Tyronib are generally dose-related and manageable with monitoring; some are common, and others are serious and require prompt medical attention.

Very Common (≥30%)

• Fluid retention/edema (periorbital or peripheral)
• Nausea and vomiting
• Muscle cramps and musculoskeletal pain
• Diarrhea
• Skin rash
• Fatigue
• Abdominal pain
• Headache

Common

• Mild to moderate liver enzyme elevations
• Cytopenias (mild anemia, neutropenia, thrombocytopenia)
• Dyspepsia, weight changes
• Dizziness, insomnia

Serious/Less Common - Require Medical Attention

• Severe fluid retention: pleural effusion, pericardial effusion, ascites, pulmonary edema, rapid weight gain (see Precautions and Warnings)
• Severe hepatotoxicity, including rare fatal liver failure (see Precautions and Warnings)
• Severe myelosuppression: Grade 3/4 neutropenia and thrombocytopenia requiring blood count monitoring
• Gastrointestinal or other hemorrhage, including from GIST tumor sites
• Cardiac dysfunction, including congestive heart failure and reduced left ventricular function (rare but serious)
• Gastrointestinal perforation (rare)
• Severe skin reactions (e.g., Stevens-Johnson syndrome - rare)
• Tumor lysis syndrome, particularly with high tumor burden at treatment initiation

Patients should seek prompt medical attention for sudden weight gain, shortness of breath, swelling, unusual bleeding or bruising, yellowing of skin/eyes, severe abdominal pain, or signs of infection.

Pregnancy: Tyronib can cause fetal harm and has shown teratogenic and embryotoxic effects in animal studies. It should not be used during pregnancy unless the potential benefit to the mother clearly justifies the potential risk to the fetus, and only after thorough discussion with the treating oncologist. Women of reproductive potential should use effective contraception during treatment with Tyronib and for at least 14 days after the last dose. If pregnancy occurs during treatment, the patient must be informed promptly of the potential risk to the fetus and referred for specialist counseling.

Lactation: Tyronib and its metabolite are excreted into human breast milk. Because of the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment with Tyronib and for at least one month after the final dose; consult the treating physician for individualized guidance.

Tyronib requires close specialist supervision and regular monitoring throughout treatment. Key precautions include:

Fluid Retention

Severe fluid retention, including pleural effusion, pericardial effusion, ascites, and pulmonary edema, has been reported, particularly at higher doses and in elderly patients or those with pre-existing cardiac disease. Monitor body weight regularly; unexpected rapid weight gain should be investigated promptly and may require dose interruption, diuretics, or other supportive care.

Hepatotoxicity

Hepatotoxicity, including rare cases of fatal liver failure and severe liver injury requiring transplantation, has been reported with Tyronib. Liver function tests (transaminases, bilirubin) should be checked before starting treatment and monitored monthly, or as clinically indicated; dose modification or interruption may be required for significant elevations.

Myelosuppression

Cytopenias (anemia, neutropenia, thrombocytopenia) are common, particularly in advanced-phase disease. Complete blood counts should be monitored weekly for the first month, biweekly for the second month, and periodically thereafter, with dose modification as needed.

Hemorrhage

Gastrointestinal and other hemorrhage, including bleeding from GIST tumor sites (which can be serious and even life-threatening), has been reported. Monitor patients for signs of bleeding, particularly early in GIST treatment.

Cardiac Toxicity

Cardiac failure and reduced left ventricular ejection fraction have been reported, more often in patients with pre-existing cardiac disease or risk factors. Patients with cardiac disease or risk factors for cardiac failure should be monitored closely, and any symptoms of heart failure evaluated and managed promptly.

Growth Retardation in Children

Growth retardation has been observed in children and pre-adolescents receiving long-term Tyronib therapy. Growth should be monitored closely in pediatric patients.

Gastrointestinal Perforation and Tumor Lysis Syndrome

Rare cases of gastrointestinal perforation have occurred. Tumor lysis syndrome may occur in patients with high tumor burden at treatment initiation; adequate hydration and monitoring of uric acid and electrolytes is recommended.

Hypothyroidism

Hypothyroidism has been reported in thyroidectomized patients receiving levothyroxine replacement who start Tyronib; thyroid function should be monitored.

Driving and Operating Machinery

Dizziness, blurred vision, or fatigue may occur; patients should exercise caution when driving or operating machinery.

Tyronib should be taken exactly as prescribed; do not stop, change, or skip doses without consulting the treating physician, and do not share this medicine with others.

There is no specific antidote for Tyronib overdose. In case of suspected overdose, seek immediate medical attention or contact emergency services/a poison control center right away. Management is supportive and symptomatic, and may include gastric decontamination measures and close observation, guided by a physician; do not attempt any specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

No overall differences in safety or efficacy of Tyronib have been reported between elderly and younger adult patients, but elderly patients may be more susceptible to fluid retention and should be monitored closely.

Hepatic Impairment

Dose adjustment is recommended in severe hepatic impairment (see Dosage and Administration); use with caution and monitor liver function closely in all patients with hepatic impairment.

Renal Impairment

Dose adjustment is recommended based on the degree of renal impairment (see Dosage and Administration); use with caution in patients with reduced kidney function.

Pediatric Patients

Established for Ph+ CML (chronic phase) and newly diagnosed Ph+ ALL in combination with chemotherapy, using weight/body-surface-area-based dosing; safety and efficacy in other indications and in very young children have not been established. Growth should be monitored during long-term pediatric use (see Precautions and Warnings).

Duration of Tyronib therapy is individualized by the treating oncologist/hematologist based on the specific indication, disease response, and tolerability. Treatment is often continued long-term (for CML, generally indefinitely as long as response is maintained, unless a physician-directed treatment-free remission trial is undertaken); for adjuvant GIST therapy, treatment is typically continued for a defined period (commonly at least one year, sometimes longer) as directed by the specialist. Patients should not stop treatment on their own even if they feel well, without consulting their physician.

Antineoplastic agents; BCR-ABL tyrosine kinase inhibitors; targeted (signal transduction) cancer therapy.

D

Tyronib is approved for use in pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase, and for newly diagnosed Ph+ acute lymphoblastic leukemia in combination with chemotherapy, using body-surface-area-based dosing (340 mg/m²/day, not to exceed 600 mg). Safety and efficacy for other indications, and in children below the age ranges studied in clinical trials, have not been established, and use in these settings should be individualized by a pediatric oncologist. Growth retardation has been reported in children on long-term therapy; growth parameters should be monitored regularly throughout treatment with Tyronib.